A recent report published by Infinium Global Research on chronic
obstructive pulmonary disease (COPD) therapeutics market provides an in-depth analysis of
segments and sub-segments in the global as well as regional chronic obstructive
pulmonary disease therapeutics market. The study also highlights the impact of
drivers, restraints, and macro indicators on the global and regional chronic
obstructive pulmonary disease therapeutics market over the short term as well
as long term. The report is a comprehensive presentation of trends, forecast
and dollar values of global chronic obstructive pulmonary disease therapeutics
market. According to the report, the global chronic obstructive pulmonary
disease therapeutics market is projected to grow at a healthy CAGR over the
forecast period of 2019-2025.
Chronic obstructive pulmonary disease is a chronic inflammatory
lung disease that causes obstructive airflow from the lungs. COPD is caused by
prolonged exposure to polluted or irritating gases and particulate matter. COPD
can result in severe heart disease, lung cancer, and other disorders. Emphysema
and chronic bronchitis are two common conditions that contribute to COPD.
Emphysema can be caused by longer exposure to cigarette smoke and other
irritating gases and particulate matter. Chronic bronchitis is an inflammation
of the lining of the bronchial tubes, which carry air to and from the air sacs
(alveoli) of the lungs. Some of the common symptoms of COPD include increased
shortness of breath, frequent coughing (with and without mucus), increased
breathlessness, wheezing and tightness in the chest. COPD is not curable yet,
but with proper management, a person can achieve good symptom control and
quality of life.
The most prominent factor affecting the growth of the chronic
obstructive pulmonary disease therapeutics market is a persistent rise in the
number of COPD cases globally. WHO report states the prevalence of 251 million
cases of COPD globally in 2016, and it is estimated that 3.17 million deaths
were caused by the disease in 2015, which is 5% of all deaths globally in the
year. Another factor supporting the growth of the market is changing life
habits, increasing the number of tobacco smokers, and prolong exposure to
polluted air environments are responsible for raising the number of chronic obstructive pulmonary disease patients. However, lack of knowledge and
awareness regarding COPD indication and symptoms, lack of precision in the
diagnosis of the disease are some major drawbacks contributing to the slow
growth of the market. On the other hand, strong pipeline drugs and rising
government initiatives will provide better opportunities for the COPD market.
Geographically, North America dominates the market and continue to
stay on top in the forecast year. An increasing number of tobacco smokers,
advanced diagnosis facilities, and raising awareness among people are some
factors affecting the growth of this region. The market in Europe for COPD will
grow with a healthy rate in the near future owing to heavy spending on R&D
and the introduction of new products into the market. Asia-Pacific region will
grow with a lucrative rate in the forecast period, increasing the prevalence of
COPD, increasing air pollution level, and growing pharmaceutical industries
will aid the growth of the market.
The report on global chronic obstructive pulmonary disease
therapeutics market covers segments such as drug class, and distribution
channel. On the basis of drug class, the sub-markets include bronchodilators,
combination, phosphodiesterase type 4 inhibitors, mucokinetics,
corticosteroids, and other drug class. On the basis of distribution channel,
the sub-markets include online pharmacies, hospital pharmacies, and retail
pharmacies.
The report provides profiles of the companies in the market such
as Pfizer Inc., Adamis Laboratories, Inc., AstraZeneca Plc, Boehringer
Ingelheim Pharmaceuticals, Inc., Novartis AG, and Sunovion Pharmaceuticals,
Inc.
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of chronic
obstructive pulmonary disease therapeutics market. Moreover, the study
highlights current market trends and provides forecast from 2019-2025. We also
have highlighted future trends in the market that will affect the demand during
the forecast period. Moreover, the competitive analysis given in each regional
market brings an insight into the market share of the leading players.
Please Choose One of them.